Evidence map›Paper›PMID 39556287›Full record

ArticleNeurochemical research2024

Naringenin Protected Against Blood Brain Barrier Breakdown after Ischemic Stroke through GSK-3β/ β-Catenin Pathway.

Yanping Yang, Liang Li, Liang Yu, Ying Xia, Zongping Fang, Shiquan Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yanping Yang *Department of Pharmacy, The First Affiliated Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, 710032, China.
Liang Li *Department of Neurosurgery, The First Affiliated Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, 710032, China.
Liang Yu *Department of Information, The First Affiliated Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, 710032, China.
Ying Xia *Department of Gastroenterology, The First Affiliated Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, 710032, China.
Zongping FangDepartment of Critical Case Medicine, Translational Research Institute of Brain and Brain-Like intelligence, Fourth People's Hospital, Tongji University, Shanghai, 200434, China. zongping03@163.com.
Shiquan WangDepartment of Anesthesiology and Perioperative Medicine, The First Affiliated Hospital, The Fourth military Medical University, Xi'an, Shaanxi, 710032, China. wangshiquan-301@163.com.

Funding

the National Natural Science Foundation of China 82171322the Shaanxi Provincial Natural Science Foundation 2023-JC-YB-652
6 · The paper itself

Abstract

Protection against blood-brain barrier (BBB) dysfunction is key to reduce the cerebral ischemia injury as its breakdown causes edema formation and extravasation of blood components and immune cells. The maintenance of BBB integrity requires the GSK-3β/β-catenin pathway activity. Naringenin (NAR), an effective monomer from Chinese herbal medicine, had potent protective effect on brain inflammatory and oxidative injury. However, whether NAR could protect the integrity of BBB during cerebral ischemia injury and the involvement of GSK-3β/β-catenin pathway in the beneficial effect of NAR was unknown. Therefore, mouse middle cerebral artery occlusion/reperfusion (IR) model was employed to answer these questions. NAR was intraperitoneally administrated once daily for 6 days immediately after IR with the dose of 10 mg/kg. BBB damage was evaluated with Evans blue. Protein levels of GSK-3β and β-catenin in vascular endothelial cells at penumbra were assessed with western blotting and immunofluorescence. The experimental data suggested that NAR improved neurological deficits, decreased the percentage of infarct volumes and neuronal apoptosis at 7d after IR. NAR improved BBB damage as evidenced by a lower permeability of Evans blue dye and upregulation of tight junction proteins such as zonula occludens-1(ZO-1), Occludin and Claudin-5. Importantly, GSK-3β/β-catenin pathway activity was related to the improvement of BBB integrity rendered by NAR. Our findings demonstrated that NAR might become a potential therapeutic drug for IR.

Indexed as

beta CateninBlood-Brain BarrierFlavanonesGlycogen Synthase Kinase 3 betaNeuroprotective AgentsAnimalsBrain IschemiaInfarction, Middle Cerebral ArteryIschemic StrokeMaleMiceMice, Inbred C57BLSignal Transductionbeta CateninCTNNB1 protein, mouseFlavanonesGlycogen Synthase Kinase 3 betanaringeninNeuroprotective AgentsBBBGSK-3βIRNaringeninβ-catenin

Identifiers

PMID39556287

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.